Drug news
EU CHMP recommends approval of Reagila (cariprazine) in schizophrenia- Gedeon Richter
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Reagila (cariprazine), from Gedeon Richter, intended for the treatment of schizophrenia. Reagila will be available as 1.5 mg, 3 mg, 4.5 mg and 6 mg hard capsules.
The European Medicines Agency accepted Richter's regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients, in April 2016.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins